The compound inhibits pituitary adenylate cyclase-activating peptide (PACAP), plasma level of which have been shown to be elevated during a migraine attack in clinical studies. People given ...

This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby stimulating platelet adenylate cyclase and increasing platelet cyclic-3 ...